The 8 Companies Propelling Taiwan’s Biopharma Industry
In the world of biotech and pharma, the promise of high returns comes hand in hand with high risks, but that’s hardly surprising. Most companies have to equip themselves with the know-how and technology to get a foothold in the international market.
At the same time, they must grapple with high development costs and lengthy trials. When one considers Taiwan's limited resources, few companies stand out, but those do bear outstanding resumes with the potential to challenge international competitors.
From the pool of biotechs and pharmas in Taiwan, we handpick 8 noteworthy companies based on their clinical progress and overseas achievements. Among them, some have even made big breakthroughs in treatments for cancer, AIDS, and Alzheimer's disease.
Others have a polished track record as a vaccine developer or an international contract development and manufacturing organization (CDMO). Through this article, you will be able to quickly understand what's trending in Taiwan's biotech scene.
At the same time, they must grapple with high development costs and lengthy trials. When one considers Taiwan's limited resources, few companies stand out, but those do bear outstanding resumes with the potential to challenge international competitors.
From the pool of biotechs and pharmas in Taiwan, we handpick 8 noteworthy companies based on their clinical progress and overseas achievements. Among them, some have even made big breakthroughs in treatments for cancer, AIDS, and Alzheimer's disease.
Others have a polished track record as a vaccine developer or an international contract development and manufacturing organization (CDMO). Through this article, you will be able to quickly understand what's trending in Taiwan's biotech scene.
GO Prime with only $1.49 now
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02